Alphamab Oncology (9966.HK) Earnings Analysis
Alphamab Oncology (9966.HK) next reports earnings on 2026-08-20, consensus EPS -0.41758 HKD. Trailing P/E -61.11.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 9966.HK next report earnings?
| Next earnings date | 2026-08-20 |
|---|---|
| Consensus EPS estimate | -0.41758 HKD |
| Revenue estimate | 0.00B |
9966.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-06-30 | 0.02397 HKD | n/a | n/a | n/a |
| 2024-12-31 | 0.2235 HKD | n/a | n/a | n/a |
9966.HK valuation and analyst view
| Trailing P/E | -61.11 |
|---|---|
| Trailing EPS | -0.11623 HKD |
| Price / book | 3.69 |
| Dividend yield | 0.00% |
| Market cap | 7.34B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Alphamab Oncology (9966.HK)'s next earnings date?
Alphamab Oncology is next scheduled to report on 2026-08-20, with a consensus EPS estimate of -0.41758 HKD and revenue estimate of 0.00B.
Did 9966.HK beat earnings last quarter?
Consensus estimate data was not available for 9966.HK's 2025-06-30 report.
What is 9966.HK's current P/E ratio and EPS?
9966.HK trades at a trailing P/E of -61.11 on trailing EPS of -0.11622812230382795 HKD.
What do analysts rate 9966.HK?
9966.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.